Given the well-recognized pathophysiological role on CKD progression of hyperfiltration and albuminuria, it is plausible that in the future SGLT2i will be considered as the “ideal companion” of RASi, or, alternatively, replace these traditional nephroprotective agents in patients that do not tolerate them because of AKI and/or hyperkalemia. Here, MMP19 is linked to chronic kidney disease.